Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effect of a combined LABA/LAMA treatment with
olodaterol/tiotropium on small airway function, autonomic nervous system and cardiac function
in COPD. The main objective is to study the acute effect of dual bronchodilation with
olodaterol/tiotropium on cardiac function measured by MRI. This work is unique as it assesses
the effects of Spiolto® Respimat® on the left-ventricular end-diastolic volume and muscle
sympathetic nerve activity, two endpoints relevant for cardiovascular disease. Furthermore,
the study concept introduces exhaled particle analysis as a measure for small airway
function, thus offering the opportunity for a mechanistic link between airway openness,
hyperinflation, and cardiac function.
Phase:
Phase 4
Details
Lead Sponsor:
Fraunhofer-Institute of Toxicology and Experimental Medicine